Fabiana Arieti

Fabiana Arieti

Auto-generated profile, based on publicly available information

Fabiana Arieti

Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Eurosurveillance
Verified
Journal Article
Open access
NHNasreen Hassoun-Kheir
Nasreen Hassoun-Kheir
MGMariana Guedes
Mariana Guedes
FAFabiana Arieti
Fabiana Arieti
MPMaria Diletta Pezzani
Maria Diletta Pezzani
PGPrimrose Beryl Gladstone
Primrose Beryl Gladstone
MKMarlieke Ea de Kraker
Marlieke Ea de Kraker
To reduce antimicrobial resistance (AMR), pathogen-specific AMR burden data are crucial to guide target selection for research and development of vaccines and monoclonal antibodies (mAbs). We identified knowledge gaps through previously conducted systematic reviews, which informed a Delphi expert consultation on future AMR research priorities and harmonisation strategies to support data-driven decision-making. Consensus (≥80% agreement) on importance and feasibility of research topics was achieved in two rounds, involving 24 of 39 and 19 of 24 invited experts, respectively. Priority pathogens and resistance profiles for future research were identified: third generation cephalosporin-resistant Klebsiella pneumoniae and Escherichia coli, for bloodstream and urinary tract infections, respectively, and meticillin-resistant Staphylococcus aureus for surgical-site infections. Prioritised high-risk populations included surgical, haemato-oncological and transplant patients. Mortality and resource use were prioritised as health-economic outcomes. The importance of age-stratified data and inclusion of a non-infected comparator group were highlighted. This agenda provides guidance for future research to fill knowledge gaps and support data-driven selection of target pathogens and populations for new preventive and treatment strategies, specifically vaccines and mAbs, to effectively address the AMR burden in Europe. These research priorities are also relevant to improve the evidence base for future AMR burden estimates.